JPH09512280A - カンプトテシン又は7−エチルカンプトテシンのラクトン安定治療薬 - Google Patents
カンプトテシン又は7−エチルカンプトテシンのラクトン安定治療薬Info
- Publication number
- JPH09512280A JPH09512280A JP7527959A JP52795995A JPH09512280A JP H09512280 A JPH09512280 A JP H09512280A JP 7527959 A JP7527959 A JP 7527959A JP 52795995 A JP52795995 A JP 52795995A JP H09512280 A JPH09512280 A JP H09512280A
- Authority
- JP
- Japan
- Prior art keywords
- parts
- cpt
- ecpt
- therapeutic agent
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(1)ラクトン形状(1a’) (式中、Rが水素原子又はエチル基を意味する)が50モル%超過のカンプトテ シン(CPT)又は7−エチルカンプトテシン(ECPT)及び(2)ジメチル イソソルバイド(DMI)又はジメチルアセトアミド(DMA)からなることを 特徴とする酸性溶液又は酸性懸濁液状の調合薬として受け入れられる治療薬。 2.pHが2−5である請求項1記載の治療薬。 3.pHが3−4である請求項2記載の治療薬。 4.前記治療薬が更に、タウロコール酸又は調合薬として受け入れられるその塩 及びポリエチレングリコールを含む請求項1,2又は3記載の治療薬。 5.CPT又はECPT1重量部当たり、1−10重量部のDMI又はDMA、 0.005−0.5重量部の調合薬として受け入れられる酸、1−10重量部の タウロコール 酸又は調合薬として受け入れられるその塩及び1−10重量部のポリエチレング リコールを含む請求項4記載の治療薬。 6.治療薬が更にベンジルアルコール又はグリセリンを含む請求項4記載の治療 薬。 7.治療薬が更にエタノール又はベンジルアルコール、ポリエチレングリコール 及び界面活性剤を含む請求項1,2又は3記載の治療薬。 8.約0.1mg−約50mg、好ましくは約0.1mg−約10.0mgのC PT又はECPT、1−10部のDMI又はDMA、0.1−0.5部の調合薬 として受け入れられる有機カルボキシル酸、5−9重量部のポリエチレングリコ ール、0.1−2.0部のエチル又はベンジルアルコール、及び1−10部の非 イオン界面活性剤からなり該部がCPT又はECPT1重量部当たりであるもの を含む請求項7記載の治療薬。 9.治療薬がクエン酸を含む請求項1,2,3,4,5,6,7又は8記載の治 療薬。 10.注射又は静脈注入に適した性状である請求項1,2,3,4,5,6,7, 8又は9記載の治療薬。 11.請求項1,2,3,4,5,6,7,8又は9記載の治療薬を含むカプセル 。 12.癌の処理用である請求項1,2,3,4,5,6,7, 8,9又は10記載の治療薬又は請求項11項記載のカプセル。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/234,131 US5604233A (en) | 1994-04-28 | 1994-04-28 | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
US08/240,035 | 1994-05-09 | ||
US08/234,131 | 1994-05-09 | ||
US08/240,035 US5597829A (en) | 1994-05-09 | 1994-05-09 | Lactone stable formulation of camptothecin and methods for uses thereof |
PCT/EP1995/001432 WO1995029677A1 (en) | 1994-04-28 | 1995-04-18 | Lactone stable formulation of camptothecin or 7-ethyl camptothecin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09512280A true JPH09512280A (ja) | 1997-12-09 |
JP4177891B2 JP4177891B2 (ja) | 2008-11-05 |
Family
ID=26927598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52795995A Expired - Fee Related JP4177891B2 (ja) | 1994-04-28 | 1995-04-18 | カンプトテシン又は7−エチルカンプトテシンのラクトン安定処方物 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0758237B1 (ja) |
JP (1) | JP4177891B2 (ja) |
CA (1) | CA2188297C (ja) |
DE (1) | DE69531611T2 (ja) |
MX (1) | MX9605131A (ja) |
WO (1) | WO1995029677A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100929320B1 (ko) * | 2001-10-31 | 2009-11-27 | 쉐링 코포레이션 | 리바비린 시럽 제형 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4428900A (en) * | 1999-01-28 | 2000-08-18 | Shshikant Prabhudas Kurani | Novel injectable muscle relaxant formulations |
GB9918885D0 (en) | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
EP1374855A1 (en) * | 2001-03-30 | 2004-01-02 | Takeda Chemical Industries, Ltd. | Medicinal solutions |
US20040258754A1 (en) * | 2003-06-18 | 2004-12-23 | Valery Alakhov | Compositions for oral administration of camptothecin and its analogs |
DE102008059201A1 (de) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ präzipitierende Arzneistofflösungen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3219529A (en) * | 1962-10-04 | 1965-11-23 | American Cyanamid Co | Stable tetracycline solutions |
US5124318A (en) * | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.R.L. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
US4927638A (en) * | 1986-10-08 | 1990-05-22 | Bristol-Myers Company | Etoposide solutions |
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
-
1995
- 1995-04-18 JP JP52795995A patent/JP4177891B2/ja not_active Expired - Fee Related
- 1995-04-18 EP EP95917929A patent/EP0758237B1/en not_active Expired - Lifetime
- 1995-04-18 MX MX9605131A patent/MX9605131A/es unknown
- 1995-04-18 WO PCT/EP1995/001432 patent/WO1995029677A1/en active IP Right Grant
- 1995-04-18 DE DE69531611T patent/DE69531611T2/de not_active Expired - Lifetime
- 1995-04-18 CA CA002188297A patent/CA2188297C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100929320B1 (ko) * | 2001-10-31 | 2009-11-27 | 쉐링 코포레이션 | 리바비린 시럽 제형 |
Also Published As
Publication number | Publication date |
---|---|
EP0758237A1 (en) | 1997-02-19 |
DE69531611D1 (en) | 2003-10-02 |
CA2188297A1 (en) | 1995-11-09 |
WO1995029677A1 (en) | 1995-11-09 |
JP4177891B2 (ja) | 2008-11-05 |
MX9605131A (es) | 1997-10-31 |
EP0758237B1 (en) | 2003-08-27 |
DE69531611T2 (de) | 2004-02-26 |
CA2188297C (en) | 2006-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4177890B2 (ja) | 10−ヒドロキシ−7−エチルカンプトテシンのラクトン安定処方物 | |
US5859023A (en) | Formulations and compositions of poorly water soluble camptothecin derivatives | |
US6673805B2 (en) | Platinum derivative pharmaceutical formulations | |
US9107925B2 (en) | Sodium channel blocker for treatment of loss of superficial sensitivity | |
US11147810B2 (en) | Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents | |
US10987338B2 (en) | Composition containing artesunate | |
US5604233A (en) | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof | |
EP2254570B1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
US11439586B2 (en) | Intratumour injection formulation | |
JPH02115126A (ja) | エトポシド溶液 | |
US5597829A (en) | Lactone stable formulation of camptothecin and methods for uses thereof | |
JP5529165B2 (ja) | 脂質低下薬を経口腔粘膜投与する処方物(formulation) | |
JPH09512280A (ja) | カンプトテシン又は7−エチルカンプトテシンのラクトン安定治療薬 | |
US5935967A (en) | Pharmaceutical formulations of highly lipophilic camptothecin derivatives | |
US11654106B2 (en) | Aqueous suspension suitable for oral administration | |
Zhao et al. | Composition containing artesunate | |
CN117797135A (zh) | 一种紫杉醇衍生物缓释剂的制备及用途 | |
TWI619716B (zh) | 含維生素c或其衍生物的替莫唑胺醫藥組成物及其製備方法 | |
WO2009056256A1 (en) | Use of megestrol acetate having improved solubility for the treatment of cancer cachexia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041221 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050322 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070911 |
|
A524 | Written submission of copy of amendment under section 19 (pct) |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070911 |
|
A072 | Dismissal of procedure |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20080122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080212 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080508 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080819 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080825 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110829 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110829 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120829 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |